Compare Raymond James Financial, Inc. (RJF) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Raymond James Financial, Inc. trades at $158.14 (market cap $30.51B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.2× Raymond James Financial, Inc.'s market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 74 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| RJF | VRTX | |
|---|---|---|
Market Cap | $30.51B | $127.55B |
Volume | 1,206,253 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $181.18 | $557.96 |
52-Week Low | $140.89 | $407.37 |
Typical Hold Time | 74 Days | 120 Days |
Enterprise Value | $24.37B | $121.68B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $157.29, down 1.4% with a bearish technical signal. The company shows strong fundamentals with consistent earnings beats, 15.4% net margin, and 18.5% ROE. Recent Q3 2026 results featured record revenues of $3.93 billion, beating estimates. Analysts maintain a Hold consensus with $184 price target, representing 17% upside potential from current levels.
RJF presents a mixed outlook with strong operational performance offset by technical weakness. The stock offers value at 13.7x P/E with dividend growth potential, but faces headwinds from rising expenses and market volatility. Institutional activity shows mixed signals with both position increases and decreases among major holders.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
